Article

Quality of Life Research

, Volume 13, Issue 1, pp 257-262

First online:

Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13

  • Wei-Chu ChieAffiliated withSchool of Public Health and Graduate Institute of Preventive Medicine, College of Public Health, National Taiwan University
  • , Chih-Hsin YangAffiliated withDepartment of Oncology, National Taiwan University Hospital
  • , Chiun HsuAffiliated withDepartment of Oncology, National Taiwan University Hospital
  • , Pan-Chyr YangAffiliated withInternal Medicine, National Taiwan University Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The purpose of this study was to test the validity and reliability of the Taiwan Chinese translation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30, version 3) and Quality of Life Questionnaire Lung Cancer-13 (QLQ-LC13) questionnaires. Consecutively 51 patients with lung cancer undergoing active chemotherapy and 48 such patients undergoing regular follow-up completed the questionnaires. The intraclass correlation between test and retest ranged from 0.46 to 0.85 for the QLQ-C30 and was 0.76 for dyspnea for the QLQ-LC13. The κ coefficients between test and retest ranged from 0.51 to 0.73 for single items of the QLQ-C30 and 0.49–0.68 for five of the nine items in the QLQ-LC13. The Cronbach's α coefficients were ≥ 0.70 for all scales of the two questionnaires apart from that of cognitive functioning. The correlation coefficients between indices measuring similar dimensions of the EORTC QLQ-C30 and the SF-36 questionnaires ranged from 0.43 to 0.73, and that between the dyspnea scales of the two EORTC questionnaires was 0.70. Patients in the follow-up group revealed higher scores of global status/quality of life, and lower scores of nausea/vomiting, as also physical functioning. The questionnaires could also detect expected adverse effects of radiotherapy, cisplatin, and paclitaxel.

EORTC QLQ-C30 EORTC QLQ-LC13 Lung cancer Quality of life